The efficacy and safety of furmonertinib in patients with advanced EGFR-mutated NSCLC and leptomeningeal metastases. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...
Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: A multicenter, open-labeled, single-arm phase II trial. Long-term treatment outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results